RNA therapeutics are a rapidly growing class of medicines that use RNA molecules to regulate, replace, or correct biological processes. Unlike traditional small-molecule drugs that mainly target proteins, RNA-based approaches can directly control gene expression, offering new ways to treat previously difficult-to-target diseases. Major types of RNA therapeutics 1. mRNA therapeutics Deliver messenger RNA to […]
Every day, billions of cells inside our bodies follow a carefully written set of instructions. These instructions are stored in our DNA — the blueprint that tells each cell when to grow, divide, repair itself, and eventually retire. But sometimes, the blueprint develops mistakes. A single damaged letter in DNA may not seem like much. […]
A major milestone for peptide therapeutics: the FDA has approved LIPFENDRA® (enlicitide), the first and only once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia. Merck and others are leading this exciting trend in macrocyclic peptides. This approval represents more than a new cholesterol therapy—it is an important milestone for the entire […]
In response to LinkedIn News editor Tanya Dua’s invitation to share perspectives on the debate around “open” versus “restricted” AI models, I would like to offer my personal viewpoint. The discussion around Anthropic’s position — as the only major AI company that has not signed the industry letter urging Washington not to restrict open-weight AI […]
More than 60,000 patients in the U.S. have already received CAR-T cell therapies, transforming treatment options for several blood cancers. However, the next major opportunity for this technology may extend far beyond oncology. As highlighted by Carl June, the same principles that allow engineered T cells to recognize and eliminate cancer cells may also be […]
Johnson & Johnson is making a renewed push into in vivo CAR-T therapy, a field that could transform how patients receive CAR-T treatments. Traditional CAR-T therapy requires: Collecting a patient’s T cells, Engineering them in a manufacturing facility, Expanding the cells, Returning them to the patient. While highly effective, this process is complex, expensive, and […]
The central dogma of molecular biology teaches us that biological information flows from DNA → RNA → protein. After translation, proteins undergo a variety of post-translational modifications, including glycosylation, phosphorylation, and other chemical changes that shape their final biological identity. These modifications can profoundly influence protein folding, stability, molecular interactions, receptor recognition, and ultimately biological […]
The remarkable success of mRNA vaccines during the COVID-19 pandemic demonstrated the power of this technology to respond rapidly to global health challenges. Beyond infectious diseases, this platform is now driving one of the most exciting advances in modern medicine: personalized cancer immunotherapy. For decades, the concept of a “cancer vaccine” was considered an ambitious […]
CAR-T therapy has achieved a major breakthrough by overcoming one of its biggest barriers: the first approval of a CAR-T therapy for the treatment of a solid tumor. CARsgen’s satricabtagene autoleucel (satri-cel, CT041) has been approved for CLDN18.2-positive, HER2-negative gastric and gastroesophageal junction adenocarcinoma—a landmark achievement after decades of struggle to apply CAR-T beyond hematologic […]
3D cell culture aims to mimic the physiological environments found in nature by allowing cells to grow and organize into more tissue-like structures, including spheroids, organoids, and scaffold-based systems. These advanced models provide more biologically relevant conditions for research, such as studying disease mechanisms, evaluating therapeutic responses, and developing personalized medicine approaches. In recent years, […]
